Literature DB >> 7726489

Inhibition of human immunodeficiency virus integrase by bis-catechols.

R L LaFemina1, P L Graham, K LeGrow, J C Hastings, A Wolfe, S D Young, E A Emini, D J Hazuda.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) integrase protein is required for the productive infection of T-lymphoid cells in culture (R. L. LaFemina, C. L. Schneider, H. L. Robbins, P. L. Callahan, K. LeGrow, E. Roth, W. A. Schleif, and E. A. Emini, J. Virol. 66:7414-7419, 1992). This observation suggests that chemical inhibitors of integrase may prevent the spread of HIV in infected individuals. In our search for such potential chemotherapeutic agents, we observed that beta-conidendrol inhibits both the sequence-dependent and sequence-independent endonucleolytic activities of integrase with comparable potencies in vitro (50% inhibitory concentration, 500 nM). Structurally related compounds tested for their abilities to inhibit integrase generated a limited structure-activity analysis which demonstrated that potency is associated with the bis-catechol structure: two pairs of adjacent hydroxyls on separate benzene rings. beta-Conidendrol did not inhibit several other endonucleases and/or phosphoryltransferases. Although beta-conidendrol was not effective in preventing HIV-1 infection in cell culture, the in vitro data demonstrate that it is possible to identify selective agents targeted against this essential HIV-1 function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726489      PMCID: PMC162534          DOI: 10.1128/AAC.39.2.320

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Genetic analysis of homomeric interactions of human immunodeficiency virus type 1 integrase using the yeast two-hybrid system.

Authors:  G V Kalpana; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

2.  Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction.

Authors:  S Carteau; J F Mouscadet; H Goulaouic; F Subra; C Auclair
Journal:  Biochem Biophys Res Commun       Date:  1993-05-14       Impact factor: 3.575

3.  Conserved residues Pro-109 and Asp-116 are required for interaction of the human immunodeficiency virus type 1 integrase protein with its viral DNA substrate.

Authors:  M Drelich; M Haenggi; J Mous
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

4.  Inhibitory effect of the polyanionic drug suramin on the in vitro HIV DNA integration reaction.

Authors:  S Carteau; J F Mouscadet; H Goulaouic; F Subra; C Auclair
Journal:  Arch Biochem Biophys       Date:  1993-09       Impact factor: 4.013

5.  A novel assay for the DNA strand-transfer reaction of HIV-1 integrase.

Authors:  D J Hazuda; J C Hastings; A L Wolfe; E A Emini
Journal:  Nucleic Acids Res       Date:  1994-03-25       Impact factor: 16.971

6.  Viral long terminal repeat substrate binding characteristics of the human immunodeficiency virus type 1 integrase.

Authors:  D J Hazuda; A L Wolfe; J C Hastings; H L Robbins; P L Graham; R L LaFemina; E A Emini
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

7.  Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds.

Authors:  J Tomassini; H Selnick; M E Davies; M E Armstrong; J Baldwin; M Bourgeois; J Hastings; D Hazuda; J Lewis; W McClements
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Inhibitors of human immunodeficiency virus integrase.

Authors:  M R Fesen; K W Kohn; F Leteurtre; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

9.  Complementation between HIV integrase proteins mutated in different domains.

Authors:  D C van Gent; C Vink; A A Groeneger; R H Plasterk
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

10.  Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex.

Authors:  A Engelman; F D Bushman; R Craigie
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

View more
  16 in total

1.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

Authors:  C M Farnet; B Wang; J R Lipford; F D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

2.  Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase.

Authors:  W E Robinson; M G Reinecke; S Abdel-Malek; Q Jia; S A Chow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  IL-22 suppresses HSV-2 replication in human cervical epithelial cells.

Authors:  Xi-Qiu Xu; Yu Liu; Biao Zhang; Hang Liu; Dan-Dan Shao; Jin-Biao Liu; Xu Wang; Li-Na Zhou; Wen-Hui Hu; Wen-Zhe Ho
Journal:  Cytokine       Date:  2019-07-22       Impact factor: 3.861

4.  Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions.

Authors:  J L Gerton; S Ohgi; M Olsen; J DeRisi; P O Brown
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase.

Authors:  P J King; W E Robinson
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism.

Authors:  C M Farnet; B Wang; M Hansen; J R Lipford; L Zalkow; W E Robinson; J Siegel; F Bushman
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription.

Authors:  J A Turpin; R W Buckheit; D Derse; M Hollingshead; K Williamson; C Palamone; M C Osterling; S A Hill; L Graham; C A Schaeffer; M Bu; M Huang; W M Cholody; C J Michejda; W G Rice
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.

Authors:  B McDougall; P J King; B W Wu; Z Hostomsky; M G Reinecke; W E Robinson
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

9.  Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds.

Authors:  D Hazuda; P Felock; J Hastings; B Pramanik; A Wolfe; G Goodarzi; A Vora; K Brackmann; D Grandgenett
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

10.  Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.

Authors:  R A Puras Lutzke; N A Eppens; P A Weber; R A Houghten; R H Plasterk
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.